Showing 3851-3860 of 8660 results for "".
- Outpatient Palliative Care Results in More Positive Experience for HS Patientshttps://practicaldermatology.com/news/empathy-and-expertise-define-positive-palliative-care-experiences-for-hs-patients/2474029/Individuals with hidradenitis suppurativa (HS) who receive outpatient palliative care (PC) reported significant improvements in wellbeing, according to findings published in Archives of Dermatological Research.
- Study Links Psoriasis Gene Regulation to Spatial Genome Changeshttps://practicaldermatology.com/news/study-links-psoriasis-gene-regulation-to-spatial-genome-changes/2474007/Results from a new study in the Journal of Investigative Dermatology showed how changes in the 3D chromatin architecture of CD4+ T cells contribute to immune dysregulation in psoriasis. "In this study, the 3D genomic
- AI Assists in Creating Aesthetic Injector Training Programhttps://practicaldermatology.com/news/ai-assists-in-creating-aesthetic-injector-training-program/2473956/Artificial intelligence was reported as significantly useful in developing an educational course for facial botulinum toxin injections, according to a new study in Journal of Drugs in Dermatology.
- Bimekizumab Results Continue to Impress for PsO, HShttps://practicaldermatology.com/news/Bimekizumab-Results-Continue-Impress-PsO-HS/2473847/Dual inhibition with bimekizumab (BIMZELX, UCB) in adults with moderate-to-severe plaque psoriasis demonstrated high efficacy and sustained clinical benefits, according to new long-term data from phase 3 trials and their open-label extensions. Among patients with psoriasis only at baseline
- Analysis: Proximity to Tanning Facilities Correlates with Increased Melanoma Incidence in New Englandhttps://practicaldermatology.com/news/analysis-proximity-to-tanning-facilities-correlates-with-increased-melanoma-incidence-in-new-england/2473824/Results from a new analysis suggest a correlation between proximity to tanning facilities and higher melanoma inc
- Dr. Raj Chovatiya: Lebrikizumab Long-Term Data Makes 'Night and Day' Differencehttps://practicaldermatology.com/news/Dr-Raj-Chovatiya-Lebrikizumab-Long-Term-Data-Makes-Night-Day-Difference/2471865/New long-term results presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, showed complete skin clearance (EASI-100 or IGA 0) at 3 years in patients with moderate-to-severe atopic dermatitis taking lebrikizumab (EBGLYSS™, Eli Lilly and Company) in the AD
- Analysis: 3D Imaging Yields Higher Costs Without Detection Benefit in High-Risk Melanoma Patientshttps://practicaldermatology.com/news/analysis-3d-imaging-and-telederm-higher-costs-without-significant-detection-benefit-in-high-risk-melanoma-patients/2471858/New research indicates 3D total-body photography (TBP) paired with sequential digital dermoscopy imaging (SDDI) leads to higher care costs without significantly improving the detection of malignant melanomas when compared to usual care for high-risk patients. <
- riSCC App Launched for Risk Stratification of cSCChttps://practicaldermatology.com/news/riSCC-App-Launched-Risk-Stratification-cSCC/2471817/The not-for-profit organization Skin Cancer Consortium Outcomes (SCOUT) announced it has launched riSCC, a data-driven clinician mobile app designed for risk stratification of cutaneous squamous cell carcinoma (cSCC) in clinical settings. SCOUT, founded in 2018, is committed to transformi
- Adverse Event Reporting in Dermatology RCTs Falls Short of CONSORT Harms Guidelines: Analysishttps://practicaldermatology.com/news/adverse-event-reporting-in-dermatology-rcts-falls-short-of-consort-harms-guidelines-analysis/2471683/A new review assessing adverse event (AE) reporting in dermatology randomized controlled trials (RCTs) has significant gaps in adherence to the Consolidated Standards of Reporting Trials (CONSORT) Harms guidelines. The systemat
- Bempikibart Shows Durable Responses, Post-Dosing Cessation for Severe AAhttps://practicaldermatology.com/news/Bempikibart-Shows-Durable-Responses-Post-Dosing-Cessation-Severe-AA/2471651/A novel IL-7/TSLP bifunctional receptor agonist has shown long-term durable responses and post-dosing cessation for patients with severe or very severe alopecia areata, according to a presentation at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, Florida, by Brett King,